B O O K - American College of Rheumatology

ACR/ARHP Poster Session C
1812. Etanercept (ETN) Plus Methotrexate (MTX) Combination
Therapy Resulted in a Better Radiographic Outcome Than
ETN Monotherapy Even in Patients with Active Rheumatoid
Arthritis Despite MTX Treatment: 104-Week Results from
the JESMR Study. Hideto Kameda 2 , Katsuaki Kanbe 7 , Eri Sato 7 ,
Yukitaka Ueki 5 , Kazuyoshi Saitoh 8 , Shouhei Nagaoka 9 , Toshihiko
Hidaka 10 , Tatsuya Atsumi 1 , Michishi Tsukano 4 , Tsuyoshi Kasama 6 ,
Shunichi Shiozawa 3 , Yoshiya Tanaka 8 , Hisashi Yamanaka 7 and
Tsutomu Takeuchi 2 , 1 Hokkaido University Graduate School
of Medicine, 2 Keio University, 3 Kobe University Hospital,
4
Kumamoto Orthopaedic Hospital, 5 Sasebo Chuo Hospital,
6
Showa University School of Medicine, 7 Tokyo Women’s Medical
University Medical Center, 8 University of Occupational and
Environmental Health, 9 Yokohama Minami Kyosai Hospital,
10
Zenjinkai Shimin-No-Mori-Hospital.
1813. Etanercept Normalizes Systemic Bone Metabolism in
Rheumatoid Arthritis Patients. Won Park 2 , Mie Jin Lim 1 , Seong
Ryul Kwon 1 , Ji Yeol Yoon 1 , Chang Gi Moon 1 and Go Eun Ju 1 , 1 Inha
University Hospital, Incheon, Republic of Korea, 2 Inha University
Hospital, Choong-Gu Incheon, Korea, Republic of.
1814. Golimumab, a Human Anti-TNFα Monoclonal Antibody
Administered Subcutaneously Every Four Weeks as
Monotherapy in Patients with Active Rheumatoid Arthritis
Despite DMARD Therapy: 24-Week Results of Clinical and
Radiographic Assessments. Tsutomu Takeuchi 5 , Masayoshi
Harigai 8 , Yoshiya Tanaka 10 , Hisashi Yamanaka 9 , Naoki Ishiguro 7 ,
Kazuhiko Yamamoto 11 , Takuya Oba 4 , Mahboob U. Rahman 1 ,
Toru Yoshinari 6 , Nobuyuki Miyasaka 2 and Takao Koike 3 ,
1
Centocor Research and Development, Inc., Malvern, PA,
2
Graduate School of Medical and Dental Sciences, Tokyo, Japan,
3
Hokkaido University Graduate School of Medicine, 4 Janssen
Pharmaceutical K.K., 5 Keio University, Toyko, Japan, 6 Mitsubishi
Tanabe Pharma Corporation, 7 Nagoya University, 8 Tokyo Medical
and Dental University, Tokyo, Japan, 9 Tokyo Womens Med Univ,
Shinjuku-ku, Tokyo, Japan, 10 University of Occupational and
Environmental Health, Kitakyushu, Japan, 11 University of Tokyo
Graduate School of Medicine, Tokyo, Japan.
1815. Golimumab, a Human Anti-TNFα Monoclonal Antibody
Administered Subcutaneously Every Four Weeks in Patients
with Active Rheumatoid Arthritis Despite Methotrexate
Therapy: 24-Week Results of Clinical and Radiographic
Assessments. Yoshiya Tanaka 10 , Masayoshi Harigai 8 ,
Tsutomu Takeuchi 4 , Hisashi Yamanaka 9 , Naoki Ishiguro 6 ,
Kazuhiko Yamamoto 7 , Takuya Oba 3 , Mahboob U. Rahman 1 ,
Toru Yoshinari 5 , Nobuyuki Miyasaka 8 and Takao Koike 2 ,
1
Centocor Research and Development, Inc., Malvern, PA,
2
Hokkaido University Graduate School of Medicine, 3 Janssen
Pharmaceutical K.K., 4 Keio University, Toyko, Japan, 5 Mitsubishi
Tanabe Pharma Corporation, 6 Nagoya University, 7 The University
of Tokyo, 8 Tokyo Medical and Dental University, Tokyo, Japan,
9
Tokyo Womens Medical University, Shinjuku-ku, Tokyo,
Japan, 10 University of Occupational and Environmental Health,
Kitakyushu, Japan.
1816. Impact of Abatacept on Circulating Dendritic Cells and
Regulatory T Cells in Rheumatoid Arthritis Patients with
Inadequate Response or Intolerance to TNF-alpha Blockers.
Emilie Shipley 1 , Christophe Richez 1 , Thomas Barnetche 2 , Cécile
Contin-Bordes 2 , Patrick Blanco 2 and Thierry Schaeverbeke 1 ,
1
Hôpital Pellegrin, Bordeaux, France, Metropolitan, 2 Hôpital
Pellegrin, France, Metropolitan.
1817. Impact of Abatacept on Synovitis and Structural Damage in
Methotrexate (MTX)-Inadequate Responders with Active
Rheumatoid Arthritis (RA): A Randomized, Controlled
Magnetic Resonance Imaging (MRI) Exploratory Study. Philip
G. Conaghan 9 , Patrick Durez 8 , Rieke Alten 6 , Gerd Burmester 4 ,
Paul P. Tak 1 , Lars Klareskog 5 , Corine Gaillez 2 , Manuela Le Bars 2 ,
Xianhuang Zhou 3 and Charles Peterfy 7 , 1 Academic Medical
Center/University of Amsterdam, Amsterdam, The Netherlands,
2
Bristol-Myers Squibb, Rueil-Malmaison, France, 3 Bristol-Myers
Squibb, Princeton, NJ, 4 Charité-Universitatsmedizin, Berlin,
Germany, 5 Karolinska University Hospital, Stockholm, Sweden,
6
Schlosspark-Klinik, University Medicine Berlin, Germany,
7
Spire Science LCC, San Francisco, CA, 8 Université Catholique de
Louvain, Brussels, Belgium, 9 University of Leeds, Leeds, UK.
1818. Key Pharmacological Parameters Support Monthly Dosing
for Golimumab. Mahboob U. Rahman 2 , Ann Cai 1 , Eilyn Lacy 1 ,
Jonathan Kay 4 , Ed C. Keystone 5 , Eric L. Matteson 3 , Chuanpu
Hu 1 , Honghui Zhou 1 and Dave Shealy 1 , 1 Centocor Research and
Development, Inc., 2 Centocor Research and Development,
Inc./Univ. of Pennsylvania School of Medicine, Malvern, PA,
3
Mayo Clinic, Rochester, MN, 4 UMass Memorial Medical Center,
Worcester, MA, 5 University of Toronto, Toronto, ON, Canada.
1819. LITHE: Tocilizumab (TCZ) Inhibits Radiographic Progression
and Improves Physical Function in Rheumatoid Arthritis (RA)
Patients (pts) at 3 Years with Maintenance of Clinical Efficacy
over Time. Joel M. Kremer 1 , Daniel E. Furst 6 , Ruben Burgos-
Vargas 3 , Jean Dudler 2 , Christopher M. Mela 5 , Emma Vernon 5
and Roy M. Fleischmann 4 , 1 Albany Medical College, Albany,
NY, 2 Hôpital Orthopédique, Epalinges, Switzerland, 3 Hospital
General de México and Universidad Nacional Autónoma de
México, Mexico City, México, Mexico, 4 Metroplex Clinical
Research Center, Dallas, TX, 5 Roche, Welwyn, United Kingdom,
6
UCLA Medical Center, Los Angeles, CA.
1820. Long-Term Efficacy of Tocilizumab (TCZ) in Patients (Pts) with
Rheumatoid Arthritis (RA) Treated up to 3.7 Years. Majed
Khraishi 3 , Rieke Alten 8 , Juan J. Gomez-Reino 2 , Warren Rizzo 1 ,
Joy Schechtman 6 , Andre Kahan 4 , Emma Vernon 5 , Monet Taylor 5
and Josef Smolen 7 , 1 Advanced Arthritis Care, Scottsdale, AZ,
2
Hospital Clínico U. de Santiago, Santiago, Spain, 3 Memorial
University of Newfoundland, St. John’s, NL, Canada, 4 Paris
Descartes University, Paris, France, 5 Roche, Welwyn, UK,
6
SunValley Arthritis Center, Peoria, AZ, 7 University Clinic for
Internal Medicine, Vienna, Austria, 8 University of Berlin, Berlin,
Germany.
1821. Mechanism of Inhibition of Joint Destruction by Rituximab
in Rheumatoid Arthritis. Maria J. H. Boumans 2 , Rogier
M. Thurlings 3 , Koen Vos 4 , Danielle M. Gerlag 3 and Paul P.
Tak 1 , 1 Academic Med Ctr/Univ of Amsterdam, Amsterdam,
The Netherlands, 2 Academic Medical Center/University of
Amsterdam, Amsterdam, Noord-Holland, The Netherlands,
3
Academic Medical Center/University of Amsterdam, 4 Academic
Medical Center/University of Amsterdam/Jan van Breemen
Institute.
1822. Monocyte Migration to the Synovium in Rheumatoid Arthritis
Patients Treated with Adalimumab. Marieke Herenius 3 , Rogier
Thurlings 4 , Carla Wijbrandts 4 , Roelof Bennink 5 , Serge Dohmen 6 ,
Carlijn Voermans 6 , Diana Wouters 2 , Elena Izmailova 7 , Daniëlle
Gerlag 4 , Berthe van Eck-Smit 5 and Paul P. Tak 1 , 1 Academic
Med Ctr/Univ of Amsterdam, Amsterdam, The Netherlands,
2
Department of Immunopathology, Sanquin Research,
Amsterdam, Noord Holland, The Netherlands, Division of Clinical
260
2010 Program Book